Wells Fargo has clawed back the Q2 earnings drop and then some, trading at $87.74 — up nearly 3% on the week and 6.7% over the past month — with the Street's divergent targets now framing what looks like a stock searching for its next catalyst.
The recovery has quietly closed much of the gap opened by the July 14 slip. Since that note was filed, short interest has crept up roughly 2% on the week to just under 1% of the free float — a level so low it tells almost no story worth trading around. The borrow market confirms the same read: cost to borrow has collapsed to 0.24%, down sharply from a brief spike above 0.9% around the earnings date, and availability is essentially unlimited, with the lending pool showing no meaningful demand for new short positions. Options positioning adds a mild wrinkle — the put/call ratio has edged to 1.34, modestly above its 20-day average of 1.28 and about 1.3 standard deviations elevated, though nowhere near the 1.58 that marked the year's most defensive reading. Taken together, the positioning picture is calm rather than charged: bears aren't pressing, and there's no squeeze dynamic building in the lending market.
The Street remains split, but the gap has started to narrow. The consensus mean target of $100.07 implies roughly 14% upside from here — down from the ~15% implied a week ago as the stock has risen faster than targets have moved. Bulls hold BofA's $102 Buy and UBS's $104 Buy, both pointing to book value expansion and core ROE of 13.3% as evidence the franchise is in better shape than the Q2 reaction suggested. The more cautious cluster — JP Morgan at $93.50 Neutral, Baird at $92 Neutral, KBW trimmed to $94 — argues the noninterest income decline and CET1 dip to 10.6% leave the margin story unresolved. Factor scores add incremental support to the bull case: EPS surprise ranks in the 88th percentile across the universe, the 30-day EPS momentum score is at the 78th percentile, and the days-to-cover rank sits at the 79th percentile — all pointing to a stock that has been consistently beating estimates and is lightly shorted relative to peers.
The institutional picture is stable. BlackRock holds 8.6% of shares, State Street 4.5%, and Capital Research added roughly 24 million shares in the most recent reported period — a meaningful build that suggests at least one large active manager has been adding conviction. Insider activity is less instructive: the cluster of executive sales on March 5, led by CEO Charles Scharf offloading $17.6 million worth at $83.93, was routine scheduled selling and is now months old. The only trade in the 90-day window is a small award-related sale in June. No insider has purchased in the visible history.
The next scheduled catalyst is the Q3 earnings print on October 13. The historical pattern from the Q2 release — a 0.18% day-one decline followed by a flat five-day drift — and the Q1 release — a 1.2% one-day gain followed by a modest five-day pullback — gives little directional signal but does suggest the stock tends to absorb earnings results quickly and reset to the macro tone. Between now and October, the focus is likely to land on whether the net interest margin stabilises from its 2.60% read and whether noninterest income can recover toward the prior quarter's $9.49 billion level — those two numbers are where the bull-bear debate between $92 and $104 ultimately gets resolved.
See the live data behind this article on ORTEX.
Open WFC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
